Status:
UNKNOWN
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms
Lead Sponsor:
Changhai Hospital
Collaborating Sponsors:
Stemirna Therapeutics
Conditions:
Advanced Esophageal Squamous Carcinoma
Gastric Adenocarcinoma
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal squ...
Detailed Description
Dr. Bin Wang developed the investigational vaccine used in this clinical trial and designed the trial protocol.For patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancrea...
Eligibility Criteria
Inclusion
- Patients aged 18 - 75 with pathologically confirmed advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma.
- Patients with advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma who have disease progression with first line chemotherapy. (1) Failure of treatment is defined as disease progression, recurrence or metastatic disease, or intolerable toxicities occurred after treatment. (2) Each line of treatment during the period of disease progression includes one or more chemotherapy drugs which are administered for not less than one cycle or even longer. Neoadjuvant/adjuvant therapy can be applied at an earlier stage of treatment. If patient has developed recurrence or metastatic disease within 24 weeks of neoadjuvant/adjuvant therapy, it is considered as one line of systemic chemotherapy. (3) Therapies that can be performed at an earlier stage are chemotherapy in conjunction with molecular targeted drugs.
- Expected survival after first dose of study drug \> 24 weeks.
- At least one measurable lesion (≥ 10 mm) for imaging assessment.
- ECOG scores 0 - 1.
- Fresh pathological tissue specimens can be obtained
- White blood cells (WBCs) ≥ 2.5×10\^9/L
- Platelets (PLT) ≥ 100×10\^9/L
- Hemoglobin, Blood (Hb) ≥ 9.0 g/dL
- MID ≥ 1.5×10\^9/L
- Lymphocyte (LY) ≥ 0.47×10\^9/L
- LY% ≥ 15%
- Serum albumin (Alb) ≥ 30 g/L
- Serum lipase (LPS) and serum amylase \< 1.5 ULN
- Serum creatinine ≤ 1.5 ULN
- Alanine aminotransferase (ALT) ≤ 2.5 ULN
- Aspartate aminotransferase (AST) ≤ 2.5 ULN
- If osseous metastasis or liver metastasis is developed and alkaline phosphatase • (ALP) \> 2.5 ULN, ALT and AST \< 1.5 ULN.
- Serum total bilirubin (TBIL) ≤ 1.5 ULN
- Prothrombin Time (PT): International Normalized Ratio (INR) \< 1.7.
- PT \< (ULN + 4) s
- All test results should be within their normal ranges, and the patient is not receiving continuous supportive care.
Exclusion
- Patients with any of the following conditions are not eligible for the study.
- Pregnant or lactating women.
- HIV positive, HCV positive, HBV DNA copies ≥ 10\^3.
- Uncontrolled active infection.
- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
- Allergic to immunotherapies and related drugs.
- Untreated brain metastases or having symptoms of brain metastases.
- Metastases to the lung: central tumor or multiple metastases.
- Patients with heart disease for which treatment is needed or with poorly controlled hypertension.
- Patients with unstable or active peptic ulcer or with alimentary tract hemorrhage.
- Patients with previous organ transplantation or in preparation for organ transplantation.
- Patients have undertaken major surgeries or have been badly injured 4 weeks before the study (blood collection), or will undertake major surgeries during the study.
- The judgment of investigators that the patient is not able to or not willing to follow the instructions of the protocol.
Key Trial Info
Start Date :
May 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03468244
Start Date
May 1 2018
End Date
December 31 2021
Last Update
February 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changhai Hospital
Shanghai, Shanghai Municipality, China